myirislogo
19 April, 2024 20:19 IST
My Last 5 Scrips
Company BSE Price (Rs) % Chg
Yes Bank 13.35 0.00
Tata Motors 137.00 41.97
Vedl 104.80 8.21
I T C 170.70 0.00
Ntpc 86.25 0.00
Clear All Clear Last
   
NSE Live
Nifty Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Nse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
BSE Live
BSE30 Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Bse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
Watch
Sector Watch
Economy Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Research
Research Reports
Snapshot-Caplin Point Laboratories Limited
Caplin Point Laboratories Limited
Sector:Pharmaceuticals Pharmaceuticals - Formulations
BSE:524742NSE:CAPLIPOINTBloomberg:CLPL@INReuters:CAPL.BO
Market Lot: 1Face Value: 2ISIN Demat: INE475E01026
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
20-SEP-17 Caplin Point Laboratories (Caplin Point) is pleased to inform that Cycle Pharmaceuticals (Cycle) has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Ketorolac Tromethamine Injection 30mg/mL. 03-SEP-15 Caplin Point Laboratories announced today that it has recieved approval from Brazil's National Health Surveillance Agency ANVISA (Agencia Nacional de Vigilancia Sani...   More..
Business Profile Future Plans
One To One
Recent news
Latest News
Caplin Steriles gets USFDA nod for Sumatriptan Injection  -IRIS 14-Jul-21
Previous

 


Brief Financials (in Rs. Mn.) 
Period ending (months)31-Dec-2017(6)30-Jun-2017(12)30-Jun-2016(12)
Net sales 2256.353700.653084.93
Other Income49.8887.7147.93
Total Income2306.233788.363132.86
Cost of goods sold1458.112702.162307.21
OPBDIT848.121086.20825.65
PAT563.36808.20597.48
Gross Block---
Equity capital--151.10
EPS (Rs.)---
DPS (Rs.)---
BV (Rs.)---
P/E range (x)---
Debt / Equity (x)---
Operating margin (% of OI)36.828.726.4
Net margin (% of OI)24.421.319.1
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Narbavi
No 3, Lakshmanan Street
T Nagar
Chennai
Tamil Nadu-600 017
PHONE
(044) 2815 6653/ 6905
FAX
(044) 2815 4952
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
� All rights reserved. IRIS Business Services Limited
Disclaimer